Latest Press Releases
More Press Releases
Traverse Bay Farms Expands Every Day Meal App With 468 Food Pairing Ideas Across 25 Gourmet Products
Northern Michigan specialty food company introduces expanded interactive guides to help customers discover easy ways to
Gain Therapeutics Announces Late-Breakers and Poster Presentations at Upcoming Scientific Conferences
BETHESDA, Md., Nov. 05, 2026 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a
Pyxis Oncology Reports Third Quarter 2026 Financial Results and Highlights Progress Toward Pivotal Development of Micvotabart Pelidotin (MICVO)
Updated Phase 1 monotherapy results in second-line and beyond recurrent/metastatic head and neck squamous cell
NetraMark’s NetraAI Solution is Named Analytics Platform of the Year in the 2026 BioTech Breakthrough Awards
The sixth annual awards program highlights NetraAI's application of explainable AI to uncover clinically meaningful
ProMIS Neurosciences to Participate in Upcoming Conferences in November
CAMBRIDGE, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) — ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage
Allot Brings IoT Security into the 5G Network to Help Protect Against AI-Driven Cyberattacks
NetworkSecure helps telcos shield business IoT devices across 4G and 5G while creating new security revenue
Perma-Fix Reports Third Quarter 2026 Results, with Sequential Growth of 39% in Revenue and 25% in Treatment Backlog from Second Quarter 2026
Treatment backlog of $19.6 million, up approximately 65% from year-end 2025 Perma-Fix Northwest now receiving both
Commerce Announces Third Quarter 2026 Financial Results
Total ARR of $357.6 Million, an Increase of 0.5% Versus Prior Year. GMV of $9.0 Billion, an Increase of 14% Versus
Entrada Therapeutics Reports Third Quarter 2026 Financial Results
— All ELEVATE-44-201 Cohort 1 participants have completed open-label dosing, with data expected to be received by
Korsana Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Completed merger with Cyclerion Therapeutics and concurrent $380 million private placement Phase 1 healthy volunteer